{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T06:24:10Z","timestamp":1785651850950,"version":"3.56.0"},"reference-count":48,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NCI Cancer Center Support","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"NIH\/NCI Cancer Center Support","award":["1U01AR077511-01"],"award-info":[{"award-number":["1U01AR077511-01"]}]},{"name":"NIH\/NCI Cancer Center Support","award":["P400PM_199318"],"award-info":[{"award-number":["P400PM_199318"]}]},{"name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases\/National Institutes of Health","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases\/National Institutes of Health","award":["1U01AR077511-01"],"award-info":[{"award-number":["1U01AR077511-01"]}]},{"name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases\/National Institutes of Health","award":["P400PM_199318"],"award-info":[{"award-number":["P400PM_199318"]}]},{"DOI":"10.13039\/501100001711","name":"wiss National Science Foundation","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"wiss National Science Foundation","doi-asserted-by":"publisher","award":["1U01AR077511-01"],"award-info":[{"award-number":["1U01AR077511-01"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"wiss National Science Foundation","doi-asserted-by":"publisher","award":["P400PM_199318"],"award-info":[{"award-number":["P400PM_199318"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Edelstein Family Chair of Pediatric Allergy-Immunology","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"The Edelstein Family Chair of Pediatric Allergy-Immunology","award":["1U01AR077511-01"],"award-info":[{"award-number":["1U01AR077511-01"]}]},{"name":"The Edelstein Family Chair of Pediatric Allergy-Immunology","award":["P400PM_199318"],"award-info":[{"award-number":["P400PM_199318"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immune-related adverse events (irAEs) frequently complicate treatment with immune checkpoint blockade (ICB) targeting CTLA-4, PD-1, and PD-L1, which are commonly used to treat solid and hematologic malignancies. The skin and gastrointestinal (GI) tract are most frequently affected by irAEs. While extensive efforts to further characterize organ-specific adverse events have contributed to the understanding and management of individual toxicities, investigations into the relationship between multi-organ toxicities have been limited. Therefore, we aimed to conduct a characterization of irAEs occurring in both the skin and gut. A retrospective analysis of two cohorts of patients treated with ICB at Memorial Sloan Kettering Cancer Center was conducted, including a cohort of patients with cutaneous irAEs (ircAEs) confirmed by dermatologists (n = 152) and a cohort of patients with biopsy-proven immune-related colitis (n = 246). Among both cohorts, 15% (61\/398) of patients developed both skin and GI irAEs, of which 72% (44\/61) patients had ircAEs preceding GI irAEs (p = 0.00013). Our study suggests that in the subset of patients who develop both ircAEs and GI irAEs, ircAEs are likely to occur first. Further prospective studies with larger sample sizes are needed to validate our findings, to assess the overall incidence of co-incident irAEs, and to determine whether ircAEs are predictors of other irAEs. This analysis highlights the development of multi-system dermatologic and gastrointestinal irAEs and underscores the importance of oncologists, gastroenterologists, and dermatologists confronted with an ircAE to remain alert for additional irAEs.<\/jats:p>","DOI":"10.3390\/cancers14122995","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:45:44Z","timestamp":1655466344000},"page":"2995","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Contribution of the Skin\u2013Gut Axis to Immune-Related Adverse Events with Multi-System Involvement"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-6506","authenticated-orcid":false,"given":"Alyce M.","family":"Kuo","sequence":"first","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5411-5661","authenticated-orcid":false,"given":"Lukas","family":"Kraehenbuehl","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA"},{"name":"Ludwig Collaborative and Swim Across America Laboratory, Parker Institute for Cancer Immunotherapy, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"King","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology & Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-3844","authenticated-orcid":false,"given":"Donald Y. M.","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health Hospital, Denver, CO 80206, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4685-9318","authenticated-orcid":false,"given":"Elena","family":"Goleva","sequence":"additional","affiliation":[{"name":"Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health Hospital, Denver, CO 80206, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea P.","family":"Moy","sequence":"additional","affiliation":[{"name":"Dermatopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5752-6212","authenticated-orcid":false,"given":"Neil J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Genitourinary Solid Tumor Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8245-9653","authenticated-orcid":false,"given":"David M.","family":"Faleck","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology & Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jaad.2020.03.131","article-title":"Immune checkpoint inhibitors to treat cutaneous malignancies","volume":"83","author":"Barrios","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-017-1278-5","article-title":"Checkpoint inhibitors in melanoma and early phase development in solid tumors: What\u2019s the future?","volume":"15","author":"Ascierto","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4111\/icu.2018.59.5.285","article-title":"Immune checkpoint inhibitors for urothelial carcinoma","volume":"59","author":"Kim","year":"2018","journal-title":"Investig. Clin. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"116713","DOI":"10.1016\/j.lfs.2019.116713","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: A bird\u2019s eye view","volume":"233","author":"Memon","year":"2019","journal-title":"Life Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1002\/cncr.33780","article-title":"Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors","volume":"127","author":"Foster","year":"2021","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti\u2013Programmed Cell Death 1 and Anti\u2013Programmed Cell Death Ligand 1 Therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management","volume":"25","author":"Muntyanu","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor\u2013related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.anai.2021.02.009","article-title":"Immune-related cutaneous adverse events due to checkpoint inhibitors","volume":"126","author":"Wang","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_12","first-page":"561","article-title":"An immunotherapy survivor population: Health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"28","author":"Hughes","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.gie.2019.09.009","article-title":"Immune checkpoint inhibitor\u2013related luminal GI adverse events","volume":"90","author":"Mody","year":"2019","journal-title":"Gastrointest. Endosc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: A systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1159\/000518543","article-title":"Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors","volume":"102","author":"Yanai","year":"2021","journal-title":"Digestion"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaad.2019.07.049","article-title":"Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study","volume":"82","author":"Molina","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non\u2013Small-Cell Lung Cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the Treatment of Non\u2013Small-Cell Lung Cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non\u2013Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression \u2014 implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1089\/dna.2010.1021","article-title":"CTLA4 CT60 Single-Nucleotide Polymorphism Is Associated with Slovenian Inflammatory Bowel Disease Patients and Regulates Expression of CTLA4 Isoforms","volume":"29","author":"Repnik","year":"2010","journal-title":"DNA Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10025","DOI":"10.3748\/wjg.v21.i34.10025","article-title":"CTLA-4andMDR1polymorphisms increase the risk for ulcerative colitis: A meta-analysis","volume":"21","author":"Zhao","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fonc.2018.00080","article-title":"Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice","volume":"8","author":"Anderson","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"108377","DOI":"10.1016\/j.clim.2020.108377","article-title":"Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation","volume":"213","author":"Yang","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nri3228","article-title":"Epithelial antimicrobial defence of the skin and intestine","volume":"12","author":"Gallo","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00384-012-1637-x","article-title":"The skin: A mirror to the gut","volume":"28","author":"Ghevariya","year":"2013","journal-title":"Int. J. Color. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3389\/fmicb.2018.01459","article-title":"The Gut Microbiome as a Major Regulator of the Gut-Skin Axis","volume":"9","author":"Salem","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1600-0625.2009.01060.x","article-title":"Is there a \u2018gut-brain-skin axis\u2019?","volume":"19","author":"Arck","year":"2010","journal-title":"Exp. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"De Pessemier, B., Grine, L., Debaere, M., Maes, A., Paetzold, B., and Callewaert, C. (2021). Gut\u2013Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions. Microorganisms, 9.","DOI":"10.3390\/microorganisms9020353"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e147614","DOI":"10.1172\/JCI147614","article-title":"Skin inflammation activates intestinal stromal fibroblasts and promotes colitis","volume":"131","author":"Dokoshi","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1111\/jdv.17253","article-title":"Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1\/PD-L1 therapy: A national retrospective study","volume":"35","author":"Juzot","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti\u2013PD-1 and anti\u2013PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Ba","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment Outcomes of Immune-Related Cutaneous Adverse Events","volume":"37","author":"Phillips","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.17855","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u2018Dermatology for cancer patients\u2019 position statement","volume":"36","author":"Apalla","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.14309\/ajg.0000000000000497","article-title":"Checkpoint Inhibitor\u2013Induced Colitis","volume":"115","author":"Bellaguarda","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jtho.2021.06.024","article-title":"Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events","volume":"16","author":"Luo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_48","unstructured":"National Comprehensive Cancer Network (2021). Management of Immunotherapy-Associated Toxicities Version 3.2021, National Comprehensive Cancer Network."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/12\/2995\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:34:20Z","timestamp":1760139260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/12\/2995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14122995"],"URL":"https:\/\/doi.org\/10.3390\/cancers14122995","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]}}}